Wall Street analysts predict that IVERIC bio Inc (NASDAQ:ISEE) will post earnings per share (EPS) of ($0.28) for the current quarter, according to Zacks. Zero analysts have issued estimates for IVERIC bio’s earnings. IVERIC bio reported earnings of ($0.53) per share in the same quarter last year, which would indicate a positive year over year growth rate of 47.2%. The company is scheduled to announce its next earnings results before the market opens on Thursday, February 27th.
On average, analysts expect that IVERIC bio will report full-year earnings of ($1.34) per share for the current financial year, with EPS estimates ranging from ($1.40) to ($1.27). For the next fiscal year, analysts expect that the company will report earnings of ($1.44) per share, with EPS estimates ranging from ($1.55) to ($1.32). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for IVERIC bio.
Several equities research analysts have weighed in on ISEE shares. ValuEngine lowered IVERIC bio from a “sell” rating to a “strong sell” rating in a research report on Tuesday, February 4th. BidaskClub lowered IVERIC bio from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Wedbush started coverage on IVERIC bio in a research report on Monday, January 6th. They issued an “outperform” rating on the stock. Finally, Cowen started coverage on IVERIC bio in a research report on Friday, January 24th. They issued an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $1.50.
Several large investors have recently added to or reduced their stakes in ISEE. Lindbrook Capital LLC bought a new position in IVERIC bio during the fourth quarter valued at about $26,000. Northern Trust Corp bought a new position in IVERIC bio during the second quarter valued at about $114,000. Alpine Global Management LLC bought a new position in IVERIC bio during the fourth quarter valued at about $151,000. Tower Research Capital LLC TRC boosted its stake in IVERIC bio by 11,914.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 18,382 shares of the company’s stock valued at $158,000 after buying an additional 18,229 shares in the last quarter. Finally, Laurion Capital Management LP bought a new position in IVERIC bio during the fourth quarter valued at about $242,000. 75.84% of the stock is owned by institutional investors.
Shares of ISEE stock traded up $0.04 on Friday, hitting $5.56. 444,300 shares of the stock traded hands, compared to its average volume of 549,021. The company has a market capitalization of $237.31 million, a PE ratio of 3.43 and a beta of 2.18. IVERIC bio has a 1-year low of $0.91 and a 1-year high of $8.97. The company’s fifty day moving average is $6.76 and its 200 day moving average is $3.92.
IVERIC bio Company Profile
IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).
Recommended Story: What is the definition of arbitrage?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.